Business Context and Reporting Period
This Form 8-K Current Report was filed by Assembly Biosciences, Inc. on April 2, 2018. The report addresses a change in executive responsibilities effective as of the filing date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
Effective April 2, 2018, Thomas E. Rollins, Chief Development Officer and a named executive officer, transitioned his executive duties and policy-making functions to Jacqueline S. Papkoff, Ph.D., the newly hired Senior Vice President, Chief Scientific Officer Microbiome. Mr. Rollins will remain with the company to focus on alliance management and development.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on future performance, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Thomas E. Rollins has stepped down from his role as Chief Development Officer regarding policy-making functions.
- Jacqueline S. Papkoff, Ph.D., has been appointed Senior Vice President, Chief Scientific Officer Microbiome.
- Mr. Rollins remains employed by the company with a shifted focus on alliance management.
- No financial data or forward-looking guidance is included in this specific filing.